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Abstract When discussing the safety of research subjects, including their
exploitation and vulnerability as well as failures in clinical research, recent com-
mentators have focused mostly on countries with low or middle-income economies.
High-income countries are seen as relatively safe and well-regulated. This article
presents irregularities in clinical trials in an EU member state, Poland, which were
revealed by the Supreme Audit Office of Poland (the NIK). Despite adopting many
European Union regulations, including European Commission directives concerning
Good Clinical Practice, these irregularities occurred. Causes as well as potential
solutions to make clinical trials more ethical and safer are discussed.
Keywords RECs  Clinical trials  Biomedical research  Poland  Central and
Eastern Europe  Failures
Introduction
In contemporary debates about research ethics, most attention is given to countries
with relatively weak regulations in this field. When talking about safety of research
subjects, exploitation, vulnerability and irregularities in clinical research, commen-
tators focus mostly on the developing countries with low or middle income
economies (Benatar 2004; Benatar and Fleischer 2007; Emanuel 2008; Emanuel et
al. 2004; Hyder et al. 2009; Levine 1999; Macklin 2004). High-income countries are
seen as relatively safe and well-regulated.
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This article discusses failures, irregularities and malpractice in clinical trials in a
European Union member state, Poland. I believe that Poland is interesting for at
least two reasons:
First, Poland had to adopt many European Union legal regulations, including two
directives concerning Good Clinical Practice (Directive 2001/20/EC, Directive
2005/28/EC). Moreover, the number of clinical trials per year carried out in Poland
is relatively high: about 30000 human subjects participate in clinical trials yearly.
About 450 new clinical trials of medical products are registered annually (Report 1,
2010). Poland is ranked 10th in the world and 1st among emerging markets in terms
of number of clinical trial sites (PricewaterhouseCoopers 2010).
Second, Poland is a relatively new EU member state (2004). A few years ago it
was also classified by The World Bank as a high-income country (The World Bank
web page). However, it is still perceived as an emerging market and transition
society. Therefore, Poland is a good example of the position of a new member state
as well as an example of possible future circumstances in countries still under
development. Lessons from Poland can benefit others.
This paper focuses on two reports published in 2010 by the Supreme Audit Office
of Poland (Najwy _zsza Izba Kontroli or the NIK) based on two audits. The first audit
was devoted to, among other items, the inspection of external sources of financial
support, including clinical research external funds. A result of an audit report was
published in July 2010. The second was devoted to an audit of supervision quality of
clinical hospitals and trials conducted in 13 clinical hospitals. That report was
published in December 2010. In both reports, many irregularities and errors were
described in the conduct of clinical research.
Auditors and Reports
Audits were performed by the Supreme Audit Office of Poland. It is the supreme
body of audit subordinate to the lower chamber of the Polish Parliament, acting in
accordance with the principle of collegiate responsibility. The NIK controls the
execution of the state budget, as well as the quality of management and potential
irregularities in public institutions. The NIK undertakes audits ordered by the lower
chamber of Parliament, the Prime Minister, the President, or on its own initiative.
The NIK is also a member of The International Organization of Supreme Audit
Institutions (INTOSAI) as well as the European Organization of Supreme Audit
Institutions (EUROSAI). The Supreme Audit Office of Poland is a politically
independent body, e.g. The NIK President is protected by immunity, and is
appointed by the lower chamber of Parliament for a 6 years term of office; the term
of office of Parliament is 4 years. With decades of activities, the Supreme Audit
Office of Poland has achieved a very high reputation.
Audits undertaken by the NIK are based on Polish legal regulations, The
International Organization of Supreme Audit Institutions Auditing Standards, the
European Implementing Guidelines for the INTOSAI Auditing Standards, the Stan-
dards of the International Federation of Accountants (IFAC) as well as on the long
experience of the NIK (http://www.nik.gov.pl/en/nik-audits/standards/).
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The NIK is one of two institutions able to perform an extensive external audit of
biomedical research. It should be stressed however, that the NIK is not competent
body to audit medical and methodological issues of biomedical research. The
second (and the main one) body able to perform an external audit is The Office for
Registration of Medicinal Products, Medical Devices and Biocidal Products.
The first audit (Report 1, 2010) was initiated by the NIK after alarming results
indicated lax controls in a Katowice hospital in 2007. The audit was planned and
previously announced by the NIK. It included inspecting external sources of
financial support, including clinical research external funds. The audit was
performed between December 2008 and June 2009, focusing on the years 2006–
2008. A report was published in July 2010. Thirteen clinical hospitals associated
with medical schools were controlled at this time. The audit encompassed at least
1959 clinical trials carried out in all controlled hospitals. Results of this audit were
quite alarming.
The second audit (Report 2, 2010) was performed because of results that caused
concern and many failures and irregularities found by the NIK during the first audit.
The NIK did not audit the scientific validity of clinical trials performed in controlled
hospitals. The second audit focused on the quality of supervision of clinical
hospitals and trials. It was conducted in 13 medical universities in Poland (which are
obliged to supervise university hospitals) by The Office for Registration of
Medicinal Products, Medical Devices and Biocidal Products as well as the Ministry
of Health. The NIK focused also on the audit agreements between medical
universities and sponsors of clinical trials as well as the functioning of Ethics
Committees (RECs) established by medical universities. The audit was conducted
between December 2009 and May 2010, focusing on the years 2006–2009. A report
was published in December 2010.
The Structure of Bodies Involved in Supervision, Organization and Conduct
of Clinical Trials
The main requirement to conduct clinical trials in Poland is to obtain approval by
the Bioethics Committee (Polish equivalent of Research Ethics Committees or
RECs) as well as permission by The Office for Registration of Medicinal Products,
Medical Devices and Biocidal Products. The President of the Office is a government
administrative authority responsible for, among others, marketing authorization of
medicinal and biocidal products, medical devices as well as, within a limited scope,
clinical trials. The Office is a public administration body supporting the President of
the Office in the realization of those matters. One of the units of the Office for
Registration is a Department for Medicinal Products Registration. The President of
the Office for Registration is elected by the government and is subordinate to the
Ministry of Health (Fig. 1).
Research Ethics Committees are independent bodies. They are created at the
medical universities (appointed by the Chancellor), regional chambers of physicians
and dentists (appointed by the Regional Council of Physicians and Dentists) and
medical research centers (appointed by the Head of the Center) (Act on professions
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of physicians and dentists 1996). Medical research projects which have been
negatively assessed by the REC could be sent to the Ethics Appeal Committee
(appointed by the Ministry of Health). Czarkowski and Ró _zanowski emphasized
that RECs’ work is not coordinated and there is no central institution that could
monitor its work (Czarkowski and Ró _zanowski 2009).
Medical universities are independent bodies, however financed mostly from the
public funds. Medical universities have the right to establish university hospitals.
University hospitals are governed by the head of the hospital, by the board and
supervised by the chancellor of the medical university. Medical universities apply for
the contracts and funds for covering the cost of certain medical procedures to the
National Health Fund (the NFZ). This is the main source of their income. The National
Health Fund is an authority responsible for, among others, planning and purchasing
publicly financed health services. Expenses of the National Health Fund are covered
by the mandatory social health insurance contributions. The National Health Fund is
managed by the President, who is appointed by the National Health Fund Council. The
Council is appointed by the Prime Minister (Kuszewski and Gericke 2005).
Findings of the Supreme Audit Office of Poland (the NIK) Audits
In the conclusion of the first report, the authors wrote: ,,In the field of clinical trials
the NIK found uneconomical, illegal and unreliable activities as well as the potential
to expose patients to harm […] Pharmaceutical companies […] have more influence
in conducting, financing and financial control of clinical research than public
institutions’’ (Report 1, 2010). The findings of the audits published in these reports
are categorized below in terms of (1) failures of the national level bodies to fulfill
their oversight and management responsibilities, (2) failures of regional and local
institutions. Such categorization facilitates analysis.
Fig. 1 The structure of the bodies described in reports published by the Supreme Audit Office of Poland
(the NIK)
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1. Failures of national level institutions
(a) The NIK judged unfavorably ,,a lack of a comprehensive system of
regulations concerning conducting, financing and financial control of
clinical research’’.
(b) The NIK criticized the unreliable supervision of the Ministry of Health
over The Office for Registration of Medicinal Products. The lack of clear
and detailed legal regulations devoted to functioning of the Central
Register of Clinical Trials (the Department of The Office for Registration
of Medicinal Products) was the main reason for the lack of reliable
verification of related documentation (Report 2, 2010).
(c) ‘‘The Office for Registration of Medicinal Products gave permission for
research conducted without reliable verification of related documentation’’
(Report 2, 2010).
(d) The most alarming examples are (1) A case of research approval given by
The Office for Registration of Medicinal Products, ignoring the fact that
the protocol for this research had been previously disapproved by the REC
(Report 2, 2010). (2) A case of research approval given by The Office for
Registration of Medicinal Products without the REC’s approval (Report 2,
2010). (3) A case of research approval given by The Office for
Registration of Medicinal Products for substantial changes in ongoing
research without the REC’s approval (Report 2, 2010).
(e) The Department of The Office for Registration of Medicinal Products—
Central Register of Clinical Trials did not collect and store full and valid
information regarding registered clinical trials (e.g. data did not contain
information regarding the number of subjects as well as basic information
about research centers participating in the research). One of the reasons for
this is a lack of detailed information describing a class of required data
collected by the Central Register of Clinical Trials in Polish law. It should
be noted that the Central Register of Clinical Trials is the only institution
in Poland collecting detailed data regarding clinical trials (Report 2,
2010).
(f) One of the most criticized irregularities was the lack of an appropriate
number of audits undertaken by The Office for Registration of Medicinal
Products, Medical Devices and Biocidal Products. The NIK considered
that as one of the causes of many other irregularities. Only 1.3 % of the
research projects were audited by this body (15 from 1130 registered
trials). Moreover, only one audit was initiated by The Office; nine were
initiated by the Food and Drug Administration (USA); three were initiated
by the European Medicines Agency. The low number of audits was the
main reason that the second audit devoted to the quality of supervision of
clinical hospitals and trials was performed (Report 1, 2010).
2. Failures of regional and local institutions
(a) Irregularities in 9 of 13 hospitals were identified as ‘‘possibly dangerous to
life or health of research subjects’’ (Report 1, 2010).
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(b) Heads of all audited hospitals did not demand from sponsors’/investiga-
tors’ ethics committees approvals and also Ministry of Health decisions, as
well as other documents required by law were not obtained. Therefore,
heads of hospitals did not have reliable information regarding the number
and types of clinical trials conducted in managed hospitals, as well as the
number of subjects involved (Report 2, 2010).
(c) Consequently, in two cases, trials started before the REC approval: The
Clinical Evaluation on Advanced Resynchronization (CLEAR) and Multi-
Center Autonomic Defibrillator Implantation Trial (MADIT) in Warsaw.
In two cases, the NIK found a lack of research protocols: Ongoing
Telmisartan Alone and in Combination with Ramipril Global Endpoint
Trial/Telmisartan Randomized Assessment Study in ACE Intolerant
Subjects with Cardiovascular Disease (ONTARGET-TRANSCEND) and
A Prospective Multicentre Registry to Evaluate the Efficacy and Safety of
Treating Patients with De Novo Coronary after Lesions with a Paclitaxel-
Eluting Coronary Stent System LUC-CHOPIN (LUC CHOPIN) in
Katowice. Moreover, a defect was discovered in one of the pacemakers
(Report 1, 2010).
(d) Many procedures performed during the research were illegally classified
as standard medical care and sponsored by the National Health Fund (the
NFZ). In addition, purchase of some of the tested samples were performed
by hospitals and paid for from public funds (the NFZ), (Report 1, 2010).
(e) In many cases, the same physician/researcher conducted multiple research
projects at the same time. In UCK Gdansk, one researcher conducted 75
research projects between 2006 and 2008 (Report 1, 2010).
(f) None of the audited hospitals registered and counted their tested samples.
Most of the samples were stored in inappropriate places, some of them
after their expiration date.
(g) The NIK unfavorably judged 11 of the 12 ethics committees (RECs)
because ,,they violated rules regulating their functioning and financing’’
(Report 2, 2010). In the case of 6 committees, the NIK found that they
approved research protocols despite lack of essential information and
important documents (e.g. lack of agreements between researchers and
research centers). In some cases, the REC’s members did not receive
project approval before the final the REC meeting. In one instance, most
of the REC’s approvals were signed only by the head of the REC, which
made them invalid (Report 2, 2010).
(h) Most of the medical universities did not fulfill the required conditions to
act as a research center (requirements for such centers are included in
legal regulations). Nevertheless, they undertook this role. In a few cases,
the heads of the clinical hospitals did not know about research initiated in
subordinate institutions (Report 2, 2010).
Most of the failures described were also violations of the principles of Good
Clinical Practice contained in adopted Directives (Table 1).
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What Can Be Learned from the Supreme Audit Office of Poland reports?
Analysis and Suggested Solutions
The Supreme Audit Office of Poland report shows that failures and irregularities in
the field of clinical trials in Poland had various causes. Some of them were based on
structural problems, such as: (1) lack of appropriate regulations, (2) lack of correct
implementation of detailed procedures or (3) confusion between rules and
definitions presented in national law and those presented in adopted Directives
(Directive 2001/20/EC, Directive 2005/28/EC). The others are caused by conditions
Table 1 Articles of the Directives 2001/20/EC and 2005/28/EC violated by the irregularities
Requirement Irregularities
2001/20/EC (Directive 2001)
Article 3, Sec. 2a A clinical trial may be initiated only if
the Ethics Committee and/or the
competent authority comes to the
conclusion that the anticipated
therapeutic and public health benefits
justify the risks and may be continued
only if compliance with this
requirement is permanently
monitored
1. CLEAR and MADIT trials in
Warsaw started before the REC
approval
2. ONTARGET-TRANSCEND and
LUC-CHOPIN trials in Katowice –
the NIK found lack of research
protocols
Article 6, Sec. 2 The Ethics Committee shall give its
opinion, before a clinical trial
commences, on any issue requested
As above
Article 9 Sec. 1 […] The sponsor may not start a
clinical trial until the Ethics
Committee has issued a favorable
opinion and inasmuch as the
competent authority of the Member
State concerned has not informed the
sponsor of any grounds for non-
acceptance
As above
Research approval given by The Office
for Registration of Medicinal
Products, despite the fact that the
protocol for this research had been
previously disapproved by the REC
Directive 2005/28/EC
Article 6 Sec 3 Communication of information
between the Ethics Committees and
the competent authorities of the
Member States shall be ensured
through appropriate and efficient
systems
Lack of appropriate and efficient
systems of communication between
RECs and other units
Article 26 Member States shall establish the
relevant procedures for verification of
good clinical practice compliance
The procedures shall include the
modalities for examining both the
study management procedures and
the conditions under which clinical
trials are planned, performed,
monitored and recorded, as well as
follow-up measures
Existing procedures seem to be
insufficient
The NIK found the lack of an
appropriate number of audits
undertaken by The Office for
Registration of Medicinal Products,
Medical Devices and Biocidal
Products
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typical for transitional societies: (4) massive and rapid changes in modernized laws
and rules, which are sometimes impossible to comprehend by the average citizen as
well as by the leaders and administrative employees of modernized institutions, (5)
habits of citizens of transitional societies not consistent with new rules, (6) the
frequent phenomenon of low ethical standards (7) an aspiration to achieve the
income and quality of life of developed societies which could badly impact research
integrity. In the countries from the region of Central and Eastern Europe, additional
factors are (8) a habit of opposition to institutions and laws of the previous historical
(‘‘Communist’’) period and (9) a paternalistic approach among medical staff.
Selected similar causes of the problems of research ethics systems were analyzed
previously by Borovečki et al. (2005), Dranseika et al. (2011), Famenka (2011),
Gefenas et al. (2010), Hyder et al. (2009), Silis (2010).
Selected identified failures 1–3 are analyzed below.
Lack of appropriate regulations
In general, the legal situation of regulated clinical trials in Poland is quite
satisfactory. It should be stressed that there is no alarming lack of appropriate law.
The most important factors influencing legal improvement were two Directives
(Directive 2001/20/EC, Directive 2005/28/EC) implemented into existing law.
The poorest regulated area is the field of conflict of interest in biomedical
research. The phenomenon of conflict of interest is barely identified. This is not a
typical problem of Polish law only, but rather of the entire Central and Eastern
Europe Region (Górski 2002; Gefenas et al. 2010; Dranseika et al. 2011). In Poland,
conflict of interest in biomedical research is identified only in the Physician’s Code
of Ethics (The Chamber of Physicians and Dentists, 2004). According to the Code, a
physician-researcher is obliged, among others, to inform the patient-participant
about the fact of the researcher’s connections with pharmaceutical companies as
well as to disclose conflicts of interest in published articles and public presentations.
Unfortunately, the legal status of the Code is not fully clear. It was legislated at the
National Convention of Physicians and applies to members of that organization.
However, the current version of the Code is criticized because of lack of consistency
with binding national law.
The second weakly regulated area, according the Supreme Audit Office, is the
field of regulation concerning financial control of clinical trials. Here new
regulations are definitely needed.
Suggestions for improvement:
(a) Central institutions It is suggested that a legal solution be introduced regarding
conflict of interest in biomedical research. It is suggested that comprehensive
regulations are implemented concerning financial control of clinical research.
A new bill, Law of clinical trials with clinical therapeutic products and
veterinary therapeutic products, regulates financial control appropriately. This
bill will complement many other legal solutions suggested by the Supreme
Audit Office reports. The current version of this bill was published by the
Ministry of Health on its web site in 2011 (Ministry of Health 2011). To make
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it valid as a binding law, the bill must be passed by the Polish Parliament and
signed by the President of Republic of Poland.
(b) Regional bodies It is strongly recommended the introduction of a conflict of
interest policy in the field of clinical research at the medical universities and
hospitals. An example of that policy could be the revised Harvard University
Policy of Individual Financial Conflict of Interest for Persons Holding Faculty
and Teaching Appointments approved in 2010 (Harvard University COI Policy
2010). Unfortunately, no action was taken on this matter in Poland after the
Supreme Audit Office reports.
Lack of correct implementation of detailed procedures
Implementation of Directives regarding Good Clinical Practice in Poland was not
preceded by detailed legal solutions. That was one of the reasons for many
irregularities and failures. The Supreme Audit Office criticized gaps in detailed
regulations devoted to the functioning of the Central Register of Clinical Trials as
well as lack of regulations describing detailed information about types of required
data collected by the Central Register of Clinical Trials.
Suggestions for improvement:
(a) Central institutions Most of the gaps in the regulation’s detailed procedures
were already filled by new legislation following the Supreme Audit Office
reports: Act of the Office for Registration of Medicinal Products, Medical
Devices and Biocidal Products (Act on the Office for Registration 2011),
Order of the Ministry of Health regarding inspection of clinical research
(Ministry of Health 2012b). However, the most important, the new bill, Law
of clinical trials with clinical therapeutic products and veterinary thera-
peutic products discussed above, has not yet been enacted into law
Unfortunately, it does not contain regulations regarding the supervision
of the REC’s activity, which is definitely required (Czarkowski and
Ró _zanowski 2009).
(b) Regional bodies In reaction to the Supreme Audit Office reports, Jagiellonian
University Medical College established a new institution: The Unit for Clinical
Research. This body is responsible for constant supervision and monitoring of
clinical trials conducted at the Medial College as well as administrative
support of the trials. The Unit for clinical research worked out Standard
Operating Procedures (SOPs) regarding the conduct of clinical trials at the
Medical College. It is suggested that other medical universities establish
similar institutions.
Confusions between rules and definitions presented in national law and those
presented in adopted Directives (Directive 2001/20/EC, Directive 2005/28/EC)
Adaptation of Directives concerning Good Clinical Practice (Directive 2001/20/EC,
Directive 2005/28/EC) were introduced into Polish law by amendment to the
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Pharmaceutical Law as well as by the orders of the Ministry of Health (Ministry of
Health 2005, 2012a). The new rules were mixed with the old rules and definitions.
The result is highly unsatisfactory. The current version of Pharmaceutical Law is
unclear, hard to understand and chaotic. Moreover, there are currently several
regulations that govern clinical trials in Poland. Definitions such as ‘‘patient’’ and
‘‘physician’’ (instead of ‘‘participant’’ and ‘‘researcher’’) ‘‘medical experiment’’,
‘‘therapeutic experiment’’ and ‘‘non-therapeutic experiment’’ are still used in Polish
law despite the fact that they were criticized harshly (Levine 1999). A lack of clarity
is definitely one of the reasons for so many irregularities in the clinical trials.
Furthermore, the outdated and often harshly criticized Polish Physician’s Code of
Ethics is not consistent with existing national law in the matter of clinical
experiments. For instance, Polish law does not allow the conduct of clinical trials
with soldiers as participants, while the Code does allow this practice (The Chamber
of Physicians and Dentists 2004).
Suggestions for improvement: It is suggested that key definitions are improved
especially those connected to biomedical research used in Polish law and to make
them coherent, clear and consistent with international documents. Some of the
improvements are included in the current version of the new bill, Law of clinical
trials with clinical therapeutic products and veterinary therapeutic products. It is
suggested that this be passed as soon as possible. It is also suggested that the
National Convention of Physicians update the Physician’s Code of Ethics to make it
consistent with Polish and international laws.
Conclusion
Failures in organizing, conducting and supervising clinical trials in Poland showed
that more attention should be given to biomedical research in countries with
regulations which seem to be appropriate. As an European Union member state,
Poland was required to adopt European Commission directives concerning Good
Clinical Practice. Unfortunately, it was not enough to stop all the irregularities. It
was demonstrated that failures could have many reasons: some are typical for
transition societies and emerging markets, the other mostly for so called post-
Communist countries. A positive side of disclosing failures described by the
Supreme Audit Office of Poland is a strong impact for legal and organizational
improvements concerning supervised areas. That lesson can benefit others,
especially, when all the improvements which are already started will continue
and be fully implemented.
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